Immunicum AB: Invitation to Immunicum's Full-Year 2021 Review and Pipeline and Strategy Outlook Held as a Hybrid Event on February 17, 2022
Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-to-treat tumors, will publish its financial results for the fourth
Source: finanznachrichten.de